Displaying 121 (all) recruiting clinical trials.
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ... -
AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
While outcomes in SR B-ALL have improved significantly, this population still accounts for approximately half of the overall burden of relapse among children with ALL ... -
A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)
The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment ... -
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The goal of this trial is to reduce treatmentrelated morbidity and mortality without adversely impacting disease free survival (DFS) in Standard Risk (SR) patients, who ... -
A Phase 3 Study of I-Metaiodobenzylguanidine or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
?The primary purpose of the study is to assess the effectiveness and safety of targeted radiopharmaceutical therapy with 131I-MIBG or crizotinib for patients with high-risk ... -
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
The primary purpose of the study is to determine if accelerated BEP ((Bleomycin, Etoposide, and cisPlatin) is effective and tolerable for patients with advanced germ ... -
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
ACNS1833 is a prospective randomized phase 3 study comparing selumetinib to CV in previously untreated LGG not associated with neurofibromatosis or BRAFV600E. This non-inferiority study ... -
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1(NF1)
The purpose of the study is to find out the safety and efficacy of the drug selumetinib in treating patients with low-grade glioma. We want ... -
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810) ADMINISTERED INTRALESIONALLY FOR PATIENTS WITH RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)
The main purpose of this study is to determine the safet and tolerability of cemiplimab. Cemiplimab-rwic is only approved by the U.S. Food and ... -
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ...